| DB ID | MyCo_3193 |
| Title | (1-3)-β-D-glucan levels in candidiasis infections in the critically ill neonate |
| Year | 2012 |
| PMID | 22913303 |
| Fungal Diseases involved | Invasive candidiasis |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | spp. |
| Organism | Candida spp. |
| Ethical Statement | The study protocol was approved by the Investigational Review Board at Amiens University Medical Center. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | France |
| Cohort | This retrospective study was performed in the NICU at Amiens University Medical Center (Amiens, France). Data were gathered between December 2010 and March 2012. We included newborns in whom a BDG assay was performed for a suspected ICI and classified as infected (n = 18) or non-infected (n = 43). |
| Cohort No. | 18 Patients and 43 control |
| Age Group | 25–41 weeks |
| P Value | p< 0.001 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
